
    
      This is a single arm, open-label, single center study evaluating the safety, feasibility,
      clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell
      carcinoma. Ten patients with metastatic or locoregional disease will be treated. The goal is
      for GLA-SE to assist the patient's own immune system in attacking the cancer cells.
    
  